title: The effects of sunitinib malate used in targeted therapy on the proliferation of HeLa cells in vitro.
abstract: OBJECTIVE
  In this study, the antiproliferative and apoptotic effects of sunitinib (SU-11248, Sutent) which is used for targeted therapy was evaluated on HeLa cell line originated from human cervix carcinoma.
  
  
  METHODS
  Three different doses of sutent (D1= 1 μM, D2= 5 μM, D3= 10 μM) were administered to cells for 72 h to determine the optimal dose.
  
  
  RESULTS
  Increase in apoptotic index (AI), decrease in mitotic index (MI) of cells and slow down in proliferation rate were achieved at the dose level of 10 μM, especially at 72 h. All these findings were statistically significant (p<0.001). In addition, anaphase bridges and existence of tripolar metaphase cells that were observed at 72 h were possibly attributable to a chromosomal instability arising from shortening of telomere.
  
  
  CONCLUSIONS
  In this study, sutent effected cell kinetic parameters significantly. These results are consistent with other studies in the literature. In addition, anaphase bridges which were seen in mitosis preparations were interpreted as shortening or degradation of the telomere.
authors.affiliation: Istanbul University, Institute of Science, Department of General Biology, Istanbul, Turkey.
authors.forename: K
authors.initials: K
authors.lastname: Tekisogullari
authors.forename: M
authors.initials: M
authors.lastname: Topcul
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006367:HeLa Cells; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008940:Mitotic Index; D058990:Molecular Targeted Therapy; D010088:Oxidoreductases / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077210:Sunitinib; D013778:Tetrazolium Salts / Q000378:metabolism; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000201:enzymology* / Q000473:pathology
chemical_list: C110656:2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium; D020533:Angiogenesis Inhibitors; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D013778:Tetrazolium Salts; D010088:Oxidoreductases; D020794:Receptor Protein-Tyrosine Kinases; D000077210:Sunitinib